Our second investigational drug candidate, nelotanserin, is a potent and highly selective inverse agonist of the 5HT2A receptor, which has been implicated in visual hallucinations and other neuropsychiatric disturbances experienced by patients living with DLB.i*

Nelotanserin is being studied in two separate Phase 2 studies. One study is in patients with DLB or Parkinson’s disease dementia (PDD) who are experiencing visual hallucinations. Another study is in patients with DLB or PDD who are experiencing REM sleep behavior disorder (RBD), in which they physically act out their dreams, impacting their quality of life and endangering their bed partners. According to the Lewy Body Dementia Association, up to 85% of patients with DLB experience visual hallucinationsii and up to 80% of patients with DLB experience RBD.iii

* Nelotanserin in not yet approved for any indication in any market.

References

  1. Wen W, Ramaswamy S, Piscitelli S, Friedhoff L. Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia. Am J Geriatr Psychiatry. 2017;25(3)(suppl):S129-S130. http://www.ajgponline.org/article/S1064-7481(17)30165-3/fulltext. Accessed August 16, 2017.
  2. Lewy Body Dementia Association. Early visual hallucinations greatly increase odds of LBD over Alzheimer's. https://www.lbda.org/content/early-visual-hallucinations-greatly-increase-odds-lbd-over-alzheimers. Accessed August 16, 2017.
  3. Lewy Body Dementia Association. Sleep disorder increases odds of DLB by five times over Alzheimer's. https://www.lbda.org/content/sleep-disorder-increases-odds-dlb-five-times-more-alzheimers. Accessed August 16, 2017.